Insulet (PODD) Tops Q4 EPS by 12c; offers outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/15/2026

1. NVDA
2. SPY
3. CRWV
4. BAC
5. BLK
6. RKLB
7. RXRX
8. NOW
9. CAT
10. PLTR

Go back to Insulet (PODD) Tops Q4 EPS by 12c; offers outlook

Insulet Corporation (PODD) PT Raised to $310 at BTIG

February 21, 2025 5:09 AM EST

BTIG analyst Marie Thibault raised the price target on Insulet Corporation (NASDAQ: PODD) to $310.00 (from $300.00) while maintaining a Buy rating.

The analyst comments "Insulet reported Q4 revenue of $597.5M (+17% y/y), beating the consensus estimate of $583M and above the top end of the ~$571-$586M guidance range. U.S. Omnipod revenue of $443.7M (+12.4% y/y) was ~$7.5M above consensus of $436.3M while International Omnipod revenue of $142.0 (+33.1% cc y/ y) was ~$2M higher than consensus. Drug Delivery sales were $11.8M (cons. $6.5M). Type 2 patients were >30% of new U.S. starts in Q4... More